Browsing Tag
biotechnology
69 posts
FDA extends review period for Humacyte’s vascular trauma treatment ATEV
The U.S. Food and Drug Administration’s review of Humacyte, Inc.’s innovative vascular trauma treatment, known as the acellular…
Recursion Pharmaceuticals and Exscientia announce merger to transform drug development
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths…
AbbVie acquires Celsius Therapeutics to enhance inflammatory disease treatment options
In a significant move within the biotechnology industry, AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, has completed…
MediLink Therapeutics, BioNTech expand partnership with new $1.8bn agreement
MediLink Therapeutics (Suzhou) Co., Ltd., a prominent clinical-stage biotech company, has entered into a significant new strategic collaboration…
Innovent Biologics reports significant clinical success with picankibart in psoriasis treatment
Innovent Biologics, Inc. (HKEX: 01801) has announced remarkable results from the CLEAR-1 Phase 3 registrational study of its…
Checkerspot and AAK forge alliance to revolutionize plant-based fats and oils sector
In a significant move towards sustainability and innovation, Checkerspot, Inc., a pioneering biotechnology company recognized for its renewable…
Merck announces over €300m investment in new bioprocessing center in South Korea
Merck has embarked on a monumental investment venture, injecting more than €300 million into the construction of a…
Balrampur Chini Mills spearheads India’s first bioplastics plant with global technological partnerships
In an unprecedented move toward sustainability, Balrampur Chini Mills Limited (BCML) has announced strategic agreements with three technology…
IM Cannabis and Kadimastem announce reverse merger deal
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC), known for its significant strides in the medical cannabis sector, has…
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.